Recent investigations have focused on the convergence of GLP|GIP|glucagon receptor activator therapies and dopaminergic signaling. While GCGR stimulators are increasingly employed for addressing type 2 T2DM, their emerging effects on reward circuits, specifically governed by dopaminergic pathways